Clinical Trial Update: PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine [Phase 2]

View source ↗

Summary

Phase 2 study evaluating PD-1 inhibitor alone or with a dendritic cell/renal cell carcinoma fusion cell vaccine in renal cell carcinoma was terminated, with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Dendritic cell/renal cell carcinoma fusion cell vaccine (Dendritic cell/renal cell carcinoma fusion cell vaccine)
• PD-1 inhibitor

Snippet

Sponsor: Beth Israel Deaconess Medical Center | Conditions: Renal Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2016-11-09